449ff09a
2021-11-03
Just speculation or something good behind?
Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics 股价早盘飙升超过 10%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":841187246,"tweetId":"841187246","gmtCreate":1635896433111,"gmtModify":1635903754577,"author":{"id":3569133365230412,"idStr":"3569133365230412","authorId":3569133365230412,"authorIdStr":"3569133365230412","name":"449ff09a","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Just speculation or something good behind?</p></body></html>","htmlText":"<html><head></head><body><p>Just speculation or something good behind?</p></body></html>","text":"Just speculation or something good behind?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/841187246","repostId":1163085565,"repostType":2,"repost":{"id":"1163085565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635862319,"share":"https://www.laohunote.com/m/news/1163085565?lang=zh_CN&edition=full","pubTime":"2021-11-02 22:11","market":"us","language":"en","title":"Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics 股价早盘飙升超过 10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163085565","media":"Tiger Newspress","summary":"Bionano Genomics shares surged more than 10% in morning trading.\n\nPersonalized medicine is the holy ","content":"<p>Bionano Genomics shares surged more than 10% in morning trading.</p><p><blockquote>Bionano Genomics 股价在早盘交易中飙升超过 10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/341f797630babaf15e0ae9aa0dbd5c7d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.</p><p><blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现，癌症治疗取得了许多突破，但该领域的临床成功通常以低至30%的缓解率为特征。研究人员认为，这些极低的应答率源于特定患者群体中核酸和整个染色体水平上的突变类型差异。实际上，癌症并不是一种铁板一块的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote></p><p> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.</p><p><blockquote>为了提高这些新型抗癌治疗的功效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像 Bionano Genomics 这样的公司发挥作用的地方。Bionano Genomicssportsa 基于非测序的光学测绘技术，称为 Saphyr 系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote></p><p> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.</p><p><blockquote>此外，该生物技术公司最近收购了领先的基因组数据分析软件公司 BioDiscovery。这项具有里程碑意义的收购可能会成为公司及其股东改变游戏规则的业务发展举措。简而言之，BioDiscovery 的 NXClinical 变异分析软件解决方案与 Saphyr 系统相结合，有可能加速光学基因组作图的普及。此外，这个潜在的一流平台最终可能会在未来几年内占据这个数十亿美元市场的巨大份额。</blockquote></p><p> Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.</p><p><blockquote>Bionano 定于 11 月 4 日公布第三季度收益。虽然生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这一关键收购的长期影响。因此，Bionano 遭受重创的股票在经历了八个月的低迷后可能最终开始显示出一些生命迹象。强调这一点的是，这家生物技术公司的股价目前相对于 52 周高点下跌了 67%。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics 股价早盘飙升超过 10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics 股价早盘飙升超过 10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-02 22:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Bionano Genomics shares surged more than 10% in morning trading.</p><p><blockquote>Bionano Genomics 股价在早盘交易中飙升超过 10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/341f797630babaf15e0ae9aa0dbd5c7d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.</p><p><blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现，癌症治疗取得了许多突破，但该领域的临床成功通常以低至30%的缓解率为特征。研究人员认为，这些极低的应答率源于特定患者群体中核酸和整个染色体水平上的突变类型差异。实际上，癌症并不是一种铁板一块的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote></p><p> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.</p><p><blockquote>为了提高这些新型抗癌治疗的功效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像 Bionano Genomics 这样的公司发挥作用的地方。Bionano Genomicssportsa 基于非测序的光学测绘技术，称为 Saphyr 系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote></p><p> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.</p><p><blockquote>此外，该生物技术公司最近收购了领先的基因组数据分析软件公司 BioDiscovery。这项具有里程碑意义的收购可能会成为公司及其股东改变游戏规则的业务发展举措。简而言之，BioDiscovery 的 NXClinical 变异分析软件解决方案与 Saphyr 系统相结合，有可能加速光学基因组作图的普及。此外，这个潜在的一流平台最终可能会在未来几年内占据这个数十亿美元市场的巨大份额。</blockquote></p><p> Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.</p><p><blockquote>Bionano 定于 11 月 4 日公布第三季度收益。虽然生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这一关键收购的长期影响。因此，Bionano 遭受重创的股票在经历了八个月的低迷后可能最终开始显示出一些生命迹象。强调这一点的是，这家生物技术公司的股价目前相对于 52 周高点下跌了 67%。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163085565","content_text":"Bionano Genomics shares surged more than 10% in morning trading.\n\nPersonalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.\nTo boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.\nWhat's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.\nBionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.","news_type":1,"symbols_score_info":{"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":3914,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["JE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":37,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/841187246"}
精彩评论